The protein corona has served as a central dogma and a nuisance to the applications of nanomedicine and nanobiotechnology for well over a decade. Here we introduce the emerging field of amyloidosis inhibition, which aims to understand and harness the interfacial phenomena associated with a nanoparticle interacting with pathogenic amyloid proteins. Much of this interaction correlates with our understanding of the protein corona, and yet much differs, as elaborated for the first time in this Perspective. Specifically, we examine the in vitro, in silico and in vivo features of the new class of "amyloid protein corona", and discuss how the interactions with nanoparticles may halt the self-assembly of amyloid proteins. As amyloidosis is driven off pathway by the nanoparticles, the oligomeric and protofibrillar populations are suppressed to ameliorate their cytotoxicity. Furthermore, as amyloid proteins spread via the transport of bodily fluids or cross seeding, amyloidosis is inherently associated with dynamic proteins and ligands to evoke the immune system. Accordingly, we ponder the structural and medical implications of the amyloid protein corona in the presence of their stimulated cytokines. Understanding and exploiting the amyloid protein corona may facilitate the development of new theranostics against a range of debilitating amyloid diseases.

中文翻译：

---

淀粉样变性抑制，蛋白质冠状的新领域

十多年来，蛋白质冠一直是纳米医学和纳米生物技术应用的中心法则和麻烦。在这里，我们介绍淀粉样变性抑制的新兴领域，其目的是了解和利用与纳米颗粒与致病性淀粉样蛋白相互作用相关的界面现象。这种相互作用在很大程度上与我们对蛋白质冠的理解相关，但也有很大不同，正如本观点首次阐述的那样。具体来说，我们研究了新型“淀粉样蛋白冠”的体外、计算机和体内特征，并讨论了与纳米颗粒的相互作用如何阻止淀粉样蛋白的自组装。由于淀粉样变性被纳米粒子驱除，寡聚体和原纤维群被抑制，从而改善了它们的细胞毒性。此外，随着淀粉样蛋白通过体液运输或交叉播种传播，淀粉样变性本质上与激发免疫系统的动态蛋白和配体相关。因此，我们思考淀粉样蛋白冠在受刺激的细胞因子存在的情况下的结构和医学意义。了解和利用淀粉样蛋白冠可能有助于开发针对一系列使人衰弱的淀粉样蛋白疾病的新治疗诊断学。